SENSEX NIFTY

Kiran Mazumdar Shaw

Nov 09, 2014 at 15:23 | Source: PTI
ICICI Bank's Chanda Kochhar and Shikha Sharma of Axis Bank follow Bhattacharya at the second and the third place respectively.
Oct 29, 2014 at 15:02 | Source: CNBC-TV18
Biocon has launched INSUpen EZ, a second-generation insulin-delivery pen device, developed by Germanys Haselmeier. This is a low-cost pen, which will help us penetrate the market in a bigger way, CMD Kiran Mazumdar-Shaw told CNBC-TV18s Ekta Batra and Nigel DSouza.
Sep 22, 2014 at 08:37 | Source: PTI
ICICI Bank chief Chanda Kochhar has been ranked second across the region, while three others - SBI's Arundhati Bhattacharya (4th), HPCL's Nishi Vasudeva (5th) and Axis Bank's Shikha Sharma (10th) - have also made it to the top 10.
Sep 19, 2014 at 12:00 | Source: CNBC-TV18
Also, Kiran Mazumdar Shaw is disappointed by the process adopted by NPPA to add drugs under price control list.
Sep 19, 2014 at 10:39 | Source: Moneycontrol.com
Silver Leaf will acquire the stake from Biocon Research (BRL), a wholly owned subsidiary of Biocon at a valuation of Rs 3800 crore, said the company in its filing to BSE, adding the transaction is subject to standard condition precedents including regulatory approvals.
Sep 18, 2014 at 19:11 | Source: PTI
"This investment reflects Syngene's leading position in the contract research and manufacturing space in Asia, acknowledging its comprehensive multidisciplinary capabilities," Biocon Chairman and Managing Director Kiran Mazumdar-Shaw said in a statement.
Sep 17, 2014 at 13:49 | Source: Moneycontrol.com
Kiran Mazumdar Shaw, CMD of the company sees it to be a huge opportunity in the diabetic market and expects the insulin analogue market to grow in double-digits.
Sep 17, 2014 at 12:17 | Source: CNBC-TV18
According to Shaw, the insulin analogue opportunity is a USD 20 billion space and the market is growing in double-digits.
Sep 01, 2014 at 18:23 | Source: CNBC-TV18
Modi and his Japanese counterpart are expected to sign several key agreements today. While consensus is expected on boosting trade and defence ties, there is no confirmation yet on the civilian nuclear agreement.
Aug 18, 2014 at 09:02 | Source: CNBC-TV18
Kiran Mazumdar-Shaw goes back the memory lane and shares her life journey with Vijay Amritraj.
Messages on Kiran Mazumdar Shaw »

stocktin

Platinum Member

55 Followers

Biocon  

which involves big bucks like the 2g,3g, coal etc.In the similar context industrialists like KMS are flower pots they r the face of Indian industry after all you cant showcase an ex custom house clearing agent like Gautam Adani to the world as the face of Indian Industry for that you need Kiran Mazumdar

6.31 PM Jun 9th

Web Messenger

Platinum Member

252226 Followers

News Now  

Source:VC Circle - The company expects its small molecule API and ANDA business to be lead revenue generator followed by research services, biosimilars and branded formulations. Biocon Ltd is India's largest biotechnology company founded by Kiran Mazumdar-Shaw in ...

2.34 PM May 7th

sanecounsel

Platinum Member

76 Followers

Biocon  

BANGALORE: Kiran Mazumdar-Shaw on Friday for the very first time used the words `succession planning`, after having built Biocon into a Rs 3,000-crore global biopharmaceutical enterprise and making it the poster child of India`s biotech prowess in a span of over three decades. The board of Biocon

11.32 AM Apr 27th

stocktin

Platinum Member

55 Followers

Biocon  

ramanujam11 : Great post & the comparision with Apple .however , I am a little queasy about your first point regarding the ipo ,statin company & the hype.Who benefited from the hype created at the time of ipo?? And if this is true then everything that Biocon and Kiran Mazumdar Shaw stand for can

11.29 AM Mar 15th

Web Messenger

Platinum Member

252226 Followers

News Now  

Source:The Hindu BusinessLine - Indian Institute of Management-Bangalore (IIM-B) has appointed Kiran Mazumdar-Shaw as the Chairperson of its board of governors. At the meeting of the board of governors on February 11, the Chairperson, Mukesh D. Ambani, expressed his decision to step down, IIM

4.35 PM Feb 19th

srikanth031
086

Gold Member

62 Followers

Biocon  

Kiran Mazumdar-Shaw, chairman and managing director of Indian biopharmaceutical company Biocon Ltd., will receive the 2014 Othmer Gold Medal at the Chemical Heritage Foundation’s 13th annual Heritage Day celebration May 15. CHF president and CEO Carsten Reinhardt said in a statement that Mazumdar

2.16 PM Jan 31st

Web Messenger

Platinum Member

252226 Followers

Biocon  

Source:Economic Times - MUMBAI: Biocon has justified the Rs 19,500-57,500 pricing for its new breast cancer drug Canmab , with the company`s chairman and managing director Kiran Mazumdar-Shaw saying that the first biosimilar version of Swiss drug maker Roche`s offering has expanded the market.

12.04 PM Jan 25th

Firstpost

Platinum Member

907 Followers

Economy  

Source:FirstPost - Even though several corporate India executives have recently joined the Aam Aadmi Party while others like Bicon`s Kiran Mazumdar shaw have praised the party for itsanti-corruption stand and, the party` s populist measures are worrying investors on Dalal Street.At the heart

1.15 PM Jan 6th

Web Messenger

Platinum Member

252226 Followers

Biocon  

Source:The Hindu BusinessLine - Rakesh Bamzai, President-Marketing, Biocon Ltd, is leaving the company to take up leadership role elsewhere. He has been associated with Biocon for 19 years.Kiran Mazumdar-Shaw, Chairperson and Managing Director, Biocon, said that Rakesh has decided to take up

7.08 PM Jan 2nd

Web Messenger

Platinum Member

252226 Followers

Biocon  

Source:The Hindu BusinessLine - Rakesh Bamzai, President-Marketing, Biocon Ltd, is leaving the company to take up leadership role elsewhere. He has been associated with Biocon for 19 years.Kiran Mazumdar-Shaw, Chairperson and Managing Director, Biocon, said that Rakesh has decided to take up

1.04 PM Jan 2nd

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.